BioRestorative Therapies filings document the regulatory record of a Nevada regenerative medicine company listed on the Nasdaq Capital Market under BRTX. Its disclosures cover BRTX-100 clinical development for chronic lumbar disc disease, the ThermoStem metabolic program, the BioCosmeceutical platform, operating results, risk factors, and the use of capital for research, development, commercialization and working capital.
Recent filings include Form 8-K reports for financial results, Regulation FD presentations, executive compensation actions and material agreements, as well as registration statements for common stock, pre-funded warrants and common stock warrants. Proxy materials describe stockholder voting matters, charter-related proposals, board governance and compensation disclosures.
BioRestorative Therapies, Inc. has a new insider report from Steven Collier Brown, who is identified as a company director. This Form 3 serves as his initial statement as a reporting person and, in the data provided, lists no buy, sell, or derivative transactions.
Biorestorative Therapies, Inc. amended executive employment agreements on July 8, 2026 so that cash severance and accelerated equity vesting are triggered only by a Change in Control involving a reorganization, merger, consolidation or sale of all or substantially all assets, rather than also by changes in share ownership or board composition.
Director David Rosa resigned on July 11, followed on July 13 by President, CEO and Chair Lance Alstodt and CFO Robert Kristal, who resigned and claimed Good Reason based on an asserted Change in Control tied to prior board changes. If their resignations were determined to be for Good Reason, they would claim approximately $2.85 million in aggregate cash severance, accelerated equity and continued benefits. The board has recorded the resignations but disputes that a Change in Control or Good Reason occurred, has initiated an investigation by special counsel into the employment agreements, and is withholding any severance or related benefits pending its outcome.
Effective July 13, 2026, director Katharyn Field was appointed Chief Executive Officer, President and interim Chief Financial Officer, Treasurer and Secretary, becoming the principal executive, financial and accounting officer. The board also elected independent directors Esha Randhawa (Class II, term to the 2028 annual meeting) and Steven Brown (Class III, term to the 2026 annual meeting), redesignated committee roles, and confirmed its audit committee financial expert.
BioRestorative Therapies, Inc. director Mika Grasso has filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. This filing lists Grasso as a director and does not report any buy, sell, or other insider transactions.
BioRestorative Therapies, Inc. director Jatinder Dhaliwal filed an initial ownership report on Form 3. The filing lists him as a director and shows no reportable transactions or derivative positions at this time, indicating there were no recent insider trades disclosed in this report.
BioRestorative Therapies, Inc. director Katharyn Field has filed an initial statement of beneficial ownership on Form 3. The filing identifies her as a director, not an officer and not a ten percent owner, and does not report any specific transactions or holdings.
BioRestorative Therapies, Inc. has entered into a new executive employment agreement with Francisco Silva, its Vice President of Research and Development, effective June 10, 2026, with a term running through June 10, 2029 and automatic one-year renewals thereafter.
Silva will receive a base salary of $575,000, eligibility for an annual cash bonus of up to 50% of salary, four weeks of vacation, and potential annual stock option grants under the 2021 Stock Incentive Plan. If he is terminated without Cause or resigns for Good Reason, he is entitled to 1.5 times the sum of salary and maximum bonus, 1.5 years of COBRA premiums paid by the company (subject to conditions), and full vesting of outstanding equity awards. A Change in Control of specified types also triggers payment of this cash severance and full equity vesting. The agreement includes confidentiality, invention assignment, and a one-year non-compete and non-solicitation covenant following termination.
BioRestorative Therapies, Inc. entered into a Revolving Loan Agreement with Bowery Group LLC, giving it the ability to draw up to $1,000,000 in revolving loans for general corporate purposes. The associated Revolving Promissory Note carries a 12% annual interest rate, rising to 16% on outstanding principal after an Event of Default, with each loan maturing one year after its closing.
The financing is tied to significant board changes. Effective June 11, 2026, three directors resigned under the agreement, and on June 12, 2026, three new lender-designated independent directors — Mika Grasso, Katharyn Field and Jatinder Dhaliwal — were appointed to the board and its key committees. The company states that each new director meets Nasdaq independence standards, and Grasso is designated as an audit committee financial expert.
BioRestorative Therapies, Inc. reported two key corporate actions. Stockholders approved an amendment to its Articles of Incorporation increasing authorized common shares from 75,000,000 to 1,500,000,000, with 9,868,606 votes for, 2,389,059 against and 179,207 abstentions.
The company also entered into new three-year employment agreements, through May 27, 2029, with CEO/Chairman/President Lance Alstodt and CFO Robert Kristal. Alstodt’s annual salary is $600,000 with an annual bonus opportunity up to 50% of salary, while Kristal’s annual salary is $350,000 with a bonus opportunity up to 40%. Both contracts include severance and accelerated equity vesting protections upon certain terminations and specified Change in Control events.
BioRestorative Therapies, Inc. reporting persons led by Auctus Fund, LLC amend their Schedule 13G to show collective beneficial ownership of 2,699,470 shares of Common Stock, representing 9.9% of the class. This total includes 1,155,914 shares owned and 1,543,556 shares issuable upon exercise of warrants.
The filing cites 25,748,170 shares outstanding as of March 23, 2026 (per the issuer's 10-Q) as the base for the percentage calculation. The warrants contain a 9.99% blocker provision that prevents exercise beyond that threshold and excludes 1,498,718 warrant shares from current beneficial ownership calculations.
BioRestorative Therapies, Inc. reported first‑quarter 2026 revenue of $23,170, similar to the prior year’s $25,000, with new product sales of its BioX cosmetic line partly offsetting lower royalty income. Operating expenses fell sharply, with research and development at $1.93M and general and administrative at $1.48M, helping narrow the net loss to $2.15M from $5.34M a year earlier.
Results were boosted by a non‑cash gain of $1.22M from remeasuring and reclassifying warrant liabilities to equity. At March 31, 2026, cash and cash equivalents were $3.11M and marketable securities were $0.48M, with working capital of $2.19M. The company completed a Rodman public offering with gross proceeds of $5.0M, providing $4.44M of net financing inflows in the quarter.
Management nonetheless states that recurring losses, negative operating cash flow of $3.81M, and limited resources raise “substantial doubt” about its ability to continue as a going concern without additional capital. The company also received a Nasdaq notice on March 26, 2026 for failing to meet the $1.00 minimum bid price requirement and is evaluating options, including a potential reverse stock split. Material weaknesses in internal control over financial reporting identified in 2025 remain unresolved, though remediation efforts are underway.